Small-cap health care company Akero Therapeutics has moved 2.3% this morning, reaching $45.36 per share. In contrast, the average analyst target price for the stock is $59.14.
Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. The company is based in the United States.
Make Sure to Consider the Following Before Buying Akero Therapeutics:
-
Akero Therapeutics has moved 442.1% over the last year.
-
AKRO has a forward P/E ratio of -13.7 based on its EPS guidance of -3.31.
-
Over the last 4 years, earnings per share (EPS) have been growing at a compounded average rate of 0.3%.
-
The company has a price to earnings growth (PEG) ratio of 1.14.
-
Its Price to Book (P/B) ratio is 6.96
Akero Therapeutics Has Negative Cash Flows
| Date Reported | Cash Flow from Operations ($ k) | Capital expenditures ($ k) | Free Cashflow ($ k) | YoY Growth (%) |
|---|---|---|---|---|
| 2022-12-31 | -92,517 | nan | -92,517 | -16.11 |
| 2021-12-31 | -79,681 | nan | -79,681 | -12.3 |
| 2020-12-31 | -70,804 | -148 | -70,952 | -99.15 |
| 2019-12-31 | -35,627 | nan | -35,627 | n/a |
Averaging $-69.69 Million over the last 4 years, Akero Therapeutics has consistently negative free cash flows. Their compounded average growth rate over this period is -26.9%, and their coefficient of variability is 35.0%.
